Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Vilin Bio Med IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2005 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 30  to  30 per share
Profile
Min Investment ₹30
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Vilin Bio Med Ltd is a cutting-edge biotechnology company focused on revolutionizing healthcare through innovative research and development. With a strong emphasis on molecular biology and genetic engineering, the company strives to unlock the potential of biomedicine to address some of the most pressing medical challenges of our time. Vilin Bio Med's dedicated team of scientists and researchers work tirelessly to discover and develop novel therapies and diagnostics that have the potential to transform patient care. Leveraging state-of-the-art technologies and advanced bioinformatics, the company aims to provide personalized and targeted solutions for a wide range of diseases, including cancer, genetic disorders, and infectious diseases. Committed to excellence and collaboration, Vilin Bio Med actively seeks partnerships with academic institutions, pharmaceutical companies, and healthcare organizations to accelerate the translation of scientific breakthroughs into tangible medical advancements. By bridging the gap between research and clinical application, Vilin Bio Med strives to improve the lives of patients worldwide and shape the future of medicine. Read More

Basic Info

Face Value 10 per share

Price 30  to  30 per share

P/E (x) 150

Sales( Cr.) 15

PAT( Cr.) 0

EPS 0.2

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Viswa Prasad Sadhanala Sadhanala Venkata Rao D. Srinivasa Reddy Ramesh Reddy Sama

Pre Issue Share Holding 100%

Post Issue Share Holding 76.9%

Listing Details:

Listing Price: 30

Listing Gain: 0%

Current Price: 46.6

Gain On Issue: 46.6 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Jun 16, 2023
Closing Date Jun 21, 2023
Allotment Jun 22, 2023
Refund Jun 23, 2023
Delivery of Shares Jun 23, 2023
Listing Date Jun 26, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 4000 120,000
Retail (Max) 1 4000 120,000
S-HNI (Min) 2 8000 240,000
S-HNI (Max) 8 32000 960,000
B-HNI (Min) 9 36000 1,080,000

Objective of the Issue

1. Augmenting additional working capital requirements 2. General Corporate Purposes.

Issue

Category Nos Bid Bid (x)
QIB 0 0 0x
NII 2000000 2560000 1.3x
Retail 2000000 8620000 4.3x
EMP 0 0 0x
Total 4000000 11200000 2.8x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Vilin Bio Med Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 17 12 11 12 16 15
Other Income 0 0 0 0 0 0
Total Income 17 12 11 12 16 15
Total Expenditure 16 11 10 10 15 14
Operating Profit 1 1 1 3 1 1
Interest 0 0 1 1 1 1
Depreciation 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 0 0 0 2 0 0
Provision for Tax 0 0 0 1 0 0
Profit After Tax 0 0 0 1 0 0
Adjustments 0 0 0 0 0 0
Profit After Adjustments 0 0 0 1 0 0
Adjusted Earnings Per Share 0.2 0.1 0 1.3 0.1 0.2

Vilin Bio Med Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 7 7 7 11 23 23
Minority's Interest 0 0 0 0 0 0
Borrowings 0 1 1 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0
Total Current Liabilities 7 5 5 6 9 5
Total Liabilities 14 14 14 18 32 28
Fixed Assets 2 2 2 2 1 1
Other Non-Current Assets 0 0 0 8 12 14
Total Current Assets 12 12 12 8 19 13
Total Assets 14 14 14 18 32 28

Vilin Bio Med Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 6
Cash Flow from Operating Activities -1 -1 0 -2 -7 0
Cash Flow from Investing Activities -0 0 0 -0 0 -1
Cash Flow from Financing Activities 2 1 -0 2 9 -5
Net Cash Inflow / Outflow 0 -0 -0 -0 2 -6
Closing Cash & Cash Equivalent 0 0 0 0 2 0

Vilin Bio Med Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.2 0.15 0.04 1.25 0.12 0.16
CEPS(Rs) 0.57 0.46 0.31 1.42 0.21 0.24
DPS(Rs) 0 0 0 0 0 0
Book NAV/Share(Rs) 8.78 8.92 8.97 10.73 16.37 16.53
Core EBITDA Margin(%) 5.35 7.12 6.83 20.9 5.17 5.31
EBIT Margin(%) 3.56 5.15 4.91 19.73 6.4 7.77
Pre Tax Margin(%) 1.15 1.38 0.4 14.47 1.42 2.06
PAT Margin (%) 0.96 1.04 0.3 10.11 1.03 1.51
Cash Profit Margin (%) 2.82 3.23 2.25 11.47 1.85 2.21
ROA(%) 1.16 0.87 0.24 7.97 0.65 0.74
ROE(%) 2.24 1.66 0.46 13.78 0.97 0.97
ROCE(%) 5.09 4.89 4.31 17.17 4.47 4.16
Receivable days 157.81 232.34 251.12 198.42 130.3 147.75
Inventory Days 45.8 65.02 70.75 46.88 61.73 109.42
Payable days 49.49 54.06 30.01 46.59 44.1 45.27
PER(x) 0 0 0 0 163.23 127.34
Price/Book(x) 0 0 0 0 1.16 1.23
Dividend Yield(%) 0 0 0 0 0 0
EV/Net Sales(x) 0.46 0.75 0.76 1.21 1.73 2.09
EV/Core EBITDA(x) 8.53 10.19 11.12 5.72 23.91 24.68
Net Sales Growth(%) 0 -30.32 -4.27 9.79 28.36 -6.3
EBIT Growth(%) 0 0.73 -8.7 341.24 -58.39 13.84
PAT Growth(%) 0 -25.22 -72.3 3605.36 -86.96 37.62
EPS Growth(%) 0 -25.22 -72.32 2974.45 -90.7 37.63
Debt/Equity(x) 0.63 0.75 0.72 0.46 0.3 0.11
Current Ratio(x) 1.76 2.19 2.22 1.24 2.01 2.75
Quick Ratio(x) 1.45 1.82 1.79 1.1 1.53 1.78
Interest Cover(x) 1.48 1.36 1.09 3.75 1.29 1.36
Total Debt/Mcap(x) 0 0 0 0 0.26 0.09

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -6% 11% -2% 0%
Operating Profit CAGR 0% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 84% NA% NA% NA%
ROE Average 1% 5% 4% 3%
ROCE Average 4% 9% 7% 7%

Company Contact Information

Vilin Bio Med Ltd.

H. No. 8-2-269/s/43, Plot No. 43 Sagar Co-operative Housing Society Road No. 2, Banjara Hills, Khairatabad

IPO Lead Manager(s)

Vilin Bio Med Ltd.

Inventure Merchant Banker Services Pvt Ltd

Registrar Info

Vilin Bio Med Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!